Related Experiment Video
Updated: Jun 15, 2026
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
Rapid single-tier serodiagnosis of Lyme disease
Rajesh Ghosh1, Hyou-Arm Joung2,3, Artem Goncharov2,3
1Bioengineering Department, University of California, Los Angeles, CA, 90095, USA.
Insights
A new point-of-care test for Lyme disease (LD) uses synthetic peptides and machine learning for rapid diagnosis. This cost-effective method achieves high accuracy, potentially replacing traditional two-tier testing for earlier treatment.
Area of Science:
- Medical Diagnostics
- Immunology
- Biotechnology
Background:
- Point-of-care (POC) testing is crucial for timely disease diagnosis in distributed healthcare settings.
- Accurate and rapid diagnosis of Lyme disease (LD) remains a challenge, often relying on complex laboratory procedures.
- Existing diagnostic methods for LD can be time-consuming and may not be suitable for immediate clinical decision-making.
Purpose of the Study:
- To develop and validate a novel POC-compatible serologic test for Lyme disease (LD).
- To leverage synthetic peptides and machine learning for sensitive and specific detection of LD antibodies.
- To create a rapid, cost-effective diagnostic tool that can improve LD diagnosis and patient management.
Main Methods:
- Development of a multiplexed panel using synthetic peptide epitopes specific to Borrelia burgdorferi antibodies (IgG and IgM).
- Integration of a machine learning-based diagnostic model with the peptide panel for data analysis.
- Validation of the test using blinded samples, including those from the CDC's LD repository, and comparison with established two-tier testing protocols.
Main Results:
- The developed POC test demonstrated high sensitivity (95.5%) and specificity (100%) in blinded validation studies.
- The test accurately differentiated between LD and look-alike diseases, matching results from lab-based two-tier testing.
- Synergistic combination of multiple peptide epitopes and machine learning enhanced diagnostic accuracy.
Conclusions:
- The novel POC serologic test offers a rapid, accurate, and cost-effective method for Lyme disease diagnosis.
- This test has the potential to replace current cumbersome two-tier testing, enabling earlier treatment and improved patient outcomes.
- The technology facilitates immune monitoring and surveillance for Lyme disease, particularly in resource-limited settings.
Abstract:
Point-of-care serological and direct antigen testing offers actionable insights for diagnosing challenging illnesses, empowering distributed health systems. Here, we report a POC-compatible serologic test for Lyme disease (LD), leveraging synthetic peptides specific to LD antibodies and a paper-based platform for rapid, and cost-effective diagnosis. Antigenic epitopes conserved across Borrelia burgdorferi genospecies, targeted by IgG and IgM antibodies, are selected to develop a multiplexed panel for detection of LD antibodies from patient sera. Multiple peptide epitopes, when combined synergistically with a machine learning-based diagnostic model achieve high sensitivity without sacrificing specificity. Blinded validation with 15 LD-positive and 15 negative samples shows 95.5% sensitivity and 100% specificity. Blind testing with the CDC's LD repository samples confirms the test accuracy, matching lab-based two-tier results, correctly differentiating between LD and look-alike diseases. This LD diagnostic test could potentially replace the cumbersome two-tier testing, improving diagnosis and enabling earlier treatment while facilitating immune monitoring and surveillance.
